Disclosed is a fully humanized monoclonal antibody that resists a complement C5 molecule. In a cell lysis inhibition experiment, the antibody inhibits an antibody-sensitized CHO cell and red blood cell lysis, and may obviously enhance the survival rate of mice in the treatment of MRL/lpr lupus erythematosus mice, and symptoms such as proteinuria, glomerulus scores, interstitial inflammation, vasculitis, meniscus/necrosis and so on in the treatment group are obviously improved. The monoclonal antibody provided by the present invention can be used for preparing an autoimmune disease treatment drug.
展开▼
